1. Generics Bulletin

Biogen Exits Joint Venture As Samsung Biologics Buys Out Bioepis

Sale Price Of $2.3bn To Be Paid Over Next Two Years

 
• By Chloe Kent

Biogen’s stake in Samsung Bioepis has been fully acquired by former partner Samsung Biologics, following an announcement of the deal in January.

Hand separating puzzle pieces
Biogen announced its decision to sell its stake in January • Source: Alamy

Samsung BioLogics has completed its full acquisition of Samsung Bioepis Co., Ltd., purchasing Biogen, Inc.’s 50% -1 equity stake in the former joint venture for $2.3bn. An initial payment of $1.0bn has now been made, with the remaining $1.25bn to be paid in instalments over the next two years.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

More from Business

What’s Next? Five Things To Look Out For In May

 
• By Dean Rudge

Generics Bulletin previews the most noteworthy and anticipated events for May 2025.

Sandoz And Henlius Join Forces With $300m Ipilimumab Deal

 
• By Dave Wallace

Sandoz has struck a deal worth up to $301m with Henlius giving it rights to a proposed ipilimumab biosimilar to Yervoy in countries across the world.

Speranza Starts Generics Offshoot In Response To Wider US Pharma Manufacturing Drive

 
• By Adam Zamecnik

Reflecting increased regulatory pressure and a wider drive towards the reshoring of pharmaceutical manufacturing to the US, Speranza has launched a new generics business called Lotus Therapeutics.